Created On: 2020-07-15
Record Count: 3
- Diabetes Treatment
- Diet System
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 253985
The Parties are amending the Agreement to inter alia provide for a reduction of royalties and certain milestone payments otherwise due, permit Licensee to use certain data relating to bremelanotide, and, have Licensor conduct one or more additional clinical trials using bremelanotide.
Licensor grants the right, at Licensees expense, to inspect and copy, or otherwise obtain from Licensor, Safety Data relating to bremelanotide, and Licensee agrees to use such Safety Data.
As amended, Licensor shall, send to Licensee the originals of all Research Records including laboratory notebooks in respect of all work done and results achieved by Licensor under the Research Collaboration.
IPSCIO Record ID: 263945
Licensed Improvements to use and otherwise Exploit the Compounds, the Licensed Products, the Licensed Patents, the Licensed Know-How and the Licensed Improvements for use within the Licensed Field.
Licensor is engaged in research regarding modulation of the activity of the MC4 receptor, including regulation of appetite for treatment of obesity, diabetes and related metabolic syndrome.
The licensed know-how is for Information relating to Compounds, including without limitation cell binding, functional and efficacy Information, including both in vitro and in vivo data, to the extent not disclosed in the Licensed Patents; Information relating to development plans and proposed activities. including but not limited to proposed work and activities with respect to chemotypes, modification of existing chemotypes, synthetic methods, formulations and routes of administration; and, Information relating to other signal transduction pathways, such as activation of MAPkinase and regulation of levels of intracellular calcium, linked to activation of MC4 receptors, including exploration of correlations to the mechanism of action of Compounds.
60/712.283 Compounds and Methods for Treating Obesity
60/712.282 Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity
SD Field means the palliative, prophylactic or therapeutic treatment of mammalian, including human, sexual dysfunction, including erectile dysfunction and all related subindications, such as organic, psychogenic or iatrogenic inability to achieve or maintain an erection, ejaculatory failure, premature ejaculation, retrograde ejaculation. inability to achieve an orgasm. and the like. and female sexual dysfunction and all related subindications, such as organic, psychogenic or iatrogenic persistent or recurrent failure to attain or maintain the lubrication-swelling response of sexual excitement until completion of sexual activitv, including inhibited orgasm, dvspareunia, hypoactive sexual desire disorder, sexual anhedonia, sexual arousal disorder, vagjnismus, and the like.
IPSCIO Record ID: 211839
Australian Provisional Patent Application No. PO 1085/96 (annexed hereto) entitled â€œTreatment of Obesityâ€ filed on 18 July 1996.
The Project means scientific research using the Research Expertise into the role of potential pharmaceutical agents on food intake, body weight control and parameters of insulin resistance and diabetes as examined in studies into therapeutic regulators of food intake and appetite.